Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants

Vaccine

Volumn 23, Issue 27, 2005, Pages 3545-3554

  Mossman, S P ^a   Evans, L S ^a   Fang, H ^a   Staas, J ^b,c   Tice, T ^b,c   Raychaudhuri, S ^a,d   Grabstein, K H ^a   Cheever, M A ^a   Johnson, M E ^a,e  

^a GLAXOSMITHKLINE   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c Brookwood Pharmaceuticals Inc   (United States)

^d InBios International   (United States)

^e Discovery Laboratories   (United States)

Author keywords

Adjuvants; CTL; Her 2 neu; Microspheres; Vaccine

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSAMINE DERIVATIVE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; MICROSPHERE; POLYGLACTIN; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ARTICLE; CANCER; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 18044390665     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.149     Document Type: Article

References (66)

1. B. Fisk, B. Chesak, M.S. Pollack, J.T. Wharton, and C.G. Ioannides Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro Cell Immunol 157 2 1994 415 427
2. B.M. Fendly, C. Kotts, D. Vetterlein, G.D. Lewis, M. Winget, and M.E. Carver The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer J Biol Response Mod 9 5 1990 449 455
3. T.M. Foy, J. Bannink, R.A. Sutherland, P.D. McNeill, G.G. Moulton, and J. Smith Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor Vaccine 19 17-19 2001 2598 2606
4. L.B. Lachman, X.M. Rao, R.H. Kremer, B. Ozpolat, G. Kiriakova, and J.E. Price DNA vaccination against neu reduces breast cancer incidence and metastasis in mice Cancer Gene Ther 8 4 2001 259 268
5. B.C. Meyer zum, N. Nicklisch, S. Rose-John, C. Peschel, and H. Bernhard Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells J Immunol 165 7 2000 4133 4140
6. J.L. Murray, D. Przepiorka, and C.G. Ioannides Clinical trials of HER-2/neu-specific vaccines Semin Oncol 27 6 Suppl 11 2000 71 75
7. G.E. Peoples, P.S. Goedegebuure, R. Smith, D.C. Linehan, I. Yoshino, and T.J. Eberlein Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide Proc Natl Acad Sci U.S.A. 92 2 1995 432 436
8. M.L. Disis, J.R. Gralow, H. Bernhard, S.L. Hand, W.D. Rubin, and M.A. Cheever Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein J Immunol 156 9 1996 3151 3158
9. I. Kawashima, S.J. Hudson, V. Tsai, S. Southwood, K. Takesako, and E. Appella The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors Hum Immunol 59 1 1998 1 14
10. Y. Ikuta, T. Okugawa, R. Furugen, Y. Nagata, Y. Takahashi, and L. Wang A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes Int J Cancer 87 4 2000 553 558
11. J. Lustgarten, M. Theobald, C. Labadie, D. LaFace, P. Peterson, and M.L. Disis Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8 Hum Immunol 52 2 1997 109 118
12. D.C. Linehan, G.E. Peoples, D.T. Hess, I.C. Summerhayes, A.S. Parikh, and P.S. Goedegebuure In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour Surg Oncol 4 1 1995 41 49
13. T. Okugawa, Y. Ikuta, Y. Takahashi, H. Obata, K. Tanida, and M. Watanabe A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals Eur J Immunol 30 11 2000 3338 3346
14. B. Fisk, T.L. Blevins, J.T. Wharton, and C.G. Ioannides Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines J Exp Med 181 6 1995 2109 2117
15. K. Kono, Y. Rongcun, J. Charo, F. Ichihara, E. Celis, and A. Sette Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes Int J Cancer 78 2 1998 202 208
16. Y. Rongcun, F. Salazar-Onfray, J. Charo, K.J. Malmberg, K. Evrin, and H. Maes Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas J Immunol 163 2 1999 1037 1044
17. B.W. Anderson, G.E. Peoples, J.L. Murray, M.A. Gillogly, D.M. Gershenson, and C.G. Ioannides Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals Clin Cancer Res 6 11 2000 4192 4200
18. P. Brossart, G. Stuhler, T. Flad, S. Stevanovic, H.G. Rammensee, and L. Kanz Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes Cancer Res 58 4 1998 732 736
19. J.L. Murray, M.E. Gillogly, D. Przepiorka, H. Brewer, N.K. Ibrahim, and D.J. Booster Toxicity immunogenicity and induction of E75-specific tumor-lytic CTLs by Her-2 peptide E75 (369-377) combined with granulocyte-macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer Clin Cancer Res 8 2002 3407 3418
20. K.L. Knutson, K. Schiffman, and M.L. Disis Immunization with a HER-2/neu helper peptide vaccine generates HER- 2/neu CD8 T-cell immunity in cancer patients J Clin Invest 107 4 2001 477 484
21. T.Z. Zaks, and S.A. Rosenberg Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors Cancer Res 58 21 1998 4902 4908
22. H.J. Zeh III, D. Perry-Lalley, M.E. Dudley, S.A. Rosenberg, and J.C. Yang High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy J Immunol 162 2 1999 989 994
23. K.L. Knutson, K. Schiffman, M.A. Cheever, and M.L. Disis Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, results in short-lived peptide-specific immunity, p369-377 Clin Cancer Res 8 5 2002 1014 1018
24. Y. Tabata, and Y. Ikada Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage Biomaterials 9 1988 356 362
25. M. Kovacsovics-Bankowski, and K.L. Rock A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules Science 267 1995 243 246
26. K.J. Maloy, A.M. Sonachie, D.T. O'Hagan, and A.M. Mowat Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles Immunology 81 1994 661 667
27. Y. Men, C. Thomasin, H.P. Merkle, B. Gander, and G. Corradin A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide Vaccine 13 1995 683 689
28. A. Moore, P. McGuirk, S. Adams, W.C. Jones, J.P. McGee, and D.T. O'Hagan Immunization with a soluble recombinant HIV protein entrapped in biodegradeable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells Vaccine 13 1995 1741 1749
29. C.D. Partidos, P. Vohar, C. Anagnostopoulou, D.H. Jones, G.H. Farrar, and M.W. Steward Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes Mol Immunol 33 1996 485 491
30. Y. Men, H. Tamber, R. Audran, B. Gander, and G. Corradin Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres Vaccine 15 12-13 1997 1405 1412
31. J. Kazzaz, J. Neidleman, M. Singh, G. Ott, and D.T. O'Hagan Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1 J Control Release 67 2-3 2000 347 356
32. D.T. O'Hagan, M. Ugozzoli, J. Barackman, M. Singh, J. Kazzaz, and K. Higgins Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1 Vaccine 18 17 2000 1793 1801
33. G. Dranoff, E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, and K. Brose Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci U.S.A. 90 8 1993 3539 3543
34. M.H. Tao, and R. Levy Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma Nature 362 6422 1993 755 758
35. M.L. Disis, H. Bernhard, F.M. Shiota, S.L. Hand, J.R. Gralow, and E.S. Huseby Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines Blood 88 1 1996 202 210
36. M.L. Disis, K.H. Grabstein, P.R. Sleath, and M.A. Cheever Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine Clin Cancer Res 5 6 1999 1289 1297
37. G. Hess, F. Kreiter, W. Kosters, and K. Deusch The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients J Viral Hepat 3 3 1996 149 153
38. J.R. Baldridge, and R.T. Crane Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines Methods 19 1 1999 103 107
39. J.R. Baldridge, and J.R. Ward Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity Vaccine 15 4 1997 395 401
40. A.G. Johnson, M.A. Tomai, Y.F. Chen, and M. Odean A comparison of the immunomodulating properties of two forms of monophosphoryl lipid A analogues J Immunother 10 6 1991 398 404
41. J.T. Ulrich, and K.R. Myers Monophosphoryl lipid A as an adjuvant. Past experiences and new directions Pharm Biotechnol 6 1995 495 524
42. J.S. Chang, M.J. Choi, T.Y. Kim, S.Y. Cho, and H.S. Cheong Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes Vaccine 17 11-12 1999 1540 1548
43. R.L. Richards, M. Rao, N.M. Wassef, G.M. Glenn, S.W. Rothwell, and C.R. Alving Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS, S malaria antigen Infect Immun 66 6 1998 2859 2865
44. V. Vantomme, C. Dantinne, N. Amrani, P. Permanne, D. Gheysen, and C. Bruck Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors J Immunother 27 2 2004 124 135
45. M. Reddish, G.D. MacLean, R.R. Koganty, J. Kan-Mitchell, V. Jones, and M.S. Mitchell Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide Int J Cancer 76 6 1998 817 823
46. L.A. Holmberg, D.V. Oparin, T. Gooley, K. Lilleby, W. Bensinger, and M.A. Reddish Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn- KLH cancer vaccine Bone Marrow Transplant 25 12 2000 1233 1241
47. S.K. Kim, G. Ragupathi, C. Musselli, S.J. Choi, Y.S. Park, and P.O. Livingston Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines Vaccine 18 7-8 1999 597 603
48. M.E. Perico, D. Mezzanzanica, E. Luison, P. Alberti, L. Panza, and G. Russo Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1 Cancer Immunol Immunother 49 6 2000 296 304
49. O. Eton, D.D. Kharkevitch, M.A. Gianan, M.I. Ross, K. Itoh, and M.W. Pride Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma Clin Cancer Res 4 3 1998 619 627
50. D.A. Johnson, C.G. Sowell, C.L. Johnson, M.T. Livesay, D.S. Keegan, and M.J. Rhodes Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs) Bioorg Med Chem Lett 9 15 1999 2273 2278
51. S. Cohen, T. Yoshioka, M. Lucarelli, L.H. Hwang, and R. Langer Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres Pharm Res 8 6 1991 713 720
52. A. Vitiello, D. Marchesini, J. Furze, L.A. Sherman, and R.W. Chesnut Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex J Exp Med 173 4 1991 1007 1015
53. Y. Nagata, R. Furugen, A. Hiasa, H. Ikeda, N. Ohta, and K. Furukawa Peptides Derived from a wild-type murine proto-oncogene c-erbB-2/Her2/neu can induce CTL and tumor suppression in syngeneic hosts J Immunol 159 1997 1336 1343
54. M.F. Mescher Surface contact requirements for activation of cytotoxic T lymphocytes J Immunol 149 7 1992 2402 2405
55. J.H. Eldridge, C.J. Hammond, J.A. Meulbroek, J.K. Staas, R.M. Gilley, and T.R. Tice Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradeable microspheres target the Peyer's patches J Control Release 11 1990 205 214
56. J.H. Eldridge, J.K. Staas, J.A. Meulbroek, J.R. McGhee, T.R. Tice, and R.M. Gilley Biodegradeable microspheres as a vaccine delivery system Mol Immun 28 3 1991 287 294
57. T. Uchida, and S. Goto Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: particle size study Biol Pharm Bull 17 9 1994 1272 1276
58. T. Uchida, S. Goto, and T.P. Foster Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation J Pharm Pharmacol 47 1994 556 560
59. M.A. Tracy, K.L. Ward, L. Firouzabadian, Y. Wang, N. Dong, and R. Qian Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro Biomaterials 20 11 1999 1057 1062
60. S. Lofthouse Immunological aspects of controlled antigen delivery Adv Drug Deliv Rev 54 6 2002 863 870
61. P.J. Morrissey, L. Bressler, L.S. Park, A. Alpert, and S. Gillis Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells J Immunol 139 4 1987 1113 1119
62. P.J. Morrissey, K.H. Grabstein, S.G. Reed, and P.J. Conlon Granulocyte-macrophage colony stimulating factor. A potent activation signal for mature macrophages and monocytes Int Arch Allergy Appl Immunol 88 1-2 1989 40 45
63. D. Hovgaard, B.T. Mortensen, S. Schifter, and N.I. Nissen Clinical pharmacokinetic studies of a human haemopoietic growth factor GM-CSF Eur J Clin Invest 22 1992 45 49
64. D.K. Pettit, J.R. Lawter, W.J. Huang, S.C. Pankey, N.S. Nightlinger, and D.H. Lynch Characterization of poly(glycolide-co-D,L-lactide)/poly(D L-lactide) microspheres for controlled release of GM-CSF Pharm Res 10 1997 1422 1430
65. C.H. Cho, B.K. Lee, S.M. Kwak, and J.D. Kim Monophosphoryl lipid A (MPL) upregulates major histocompatibility complex (MHC) class I expression by increasing interferon-gamma (IFN-gamma) Yonsei Med J 40 1 1999 20 25
66. M.J. Bevan Helping the CD8+ T-cell response Nat Rev Immunol 4 2004 595 602